Comparison of low eGFR prevalence and prediction of all-cause and cardiovascular mortality using 2009 and 2021 CKD-EPI equations in Mexican adults

Daniel Ramírez-García[1,2*], Carlos A. Fermín-Martínez[1,3*], Paulina Sánchez Castro[1,2*], Brenda Guadalupe Cortez-Flores[4], Jerónimo Perezalonso Espinosa[1,3], Juan Pablo Díaz-Sánchez[1,3], Karime Berenice Carrillo-Herrera[1,3], Leslie Alitzel Cabrera-Quintana[1,3], Jaime Berumen-Campos[5], Pablo Kuri-Morales[6], Roberto Tapia-Conyer[5], Jacqueline A. Seiglie[7,8], Jesus Alegre-Díaz[5], Neftali Eduardo Antonio-Villa[9], Omar Yaxmehen Bello-Chavolla[1]

These authors contributed equally to the drafting of this work

[1]Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico. [2]Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. [3]MD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. [4]Department of Nephrology, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico. [5]Experimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico. [6]Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico. [7]Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. [8]Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. [9]Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

Correspondence: Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional de Geriatría. Anillo Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City, Mexico. Phone: +52 (55) 5548486885. E-mail: oybello@inger.gob.mx

Disclosures: The authors declare that they have no conflict of interests.

Funding: This research was supported by Instituto Nacional de Geriatría in Mexico.

Word Count: 3,514. **References:** 38 references. **Figures:** 3. **Tables:** 2.

Short Title: Comparison of CKD equations in Mexican adults

ABSTRACT (252 WORDS)

BACKGROUND: Accurate estimation of glomerular filtration rate (eGFR) is essential for identifying and managing chronic kidney disease (CKD). The CKD-EPI 2021 equation removed the race coefficient from the 2009 version, but its impact in Mexican populations remains unclear.

OBJECTIVE: To compare eGFR category prevalence and the prognostic performance of the CKD-EPI 2009 and 2021 creatinine-based eGFR equations in Mexican adults.

METHODS: We evaluated 25,236 adults ≥20 years from the 2016-2023 cycles of the Mexican National Health and Nutrition Survey (ENSANUT) to estimate national CKD and eGFR category prevalence using both equations. We also assessed 10-year all-cause and cardiovascular mortality risk in 143,410 adults from the Mexico City Prospective Study (MCPS) using adjusted Cox regression models.

RESULTS: In ENSANUT 2023, prevalence of eGFR <60mL/min/1.73m2 was lower with CKD-EPI 2021 (2.8% 95%CI 1.47-4.13) compared to 2009 (3.4% 95%CI 1.79-5.01). The 2021 equation resulted in upward reclassification of eGFR in 6.2% of adults, particularly among older adults and those with hypertension or diabetes, yielding a reduction in 496,362 adults identified with eGFR <60mL/min/1.73m^2 compared to the 2009 equation. In MCPS, upward reclassification between eGFR categories occurred in 8.3% of participants, and both equations showed similar discrimination for 10-year all-cause (c-statistics: 0.672 for both) and cardiovascular mortality (0.686 vs. 0.685), with similar performance and calibration.

CONCLUSIONS: The CKD-EPI 2021 equation yields lower prevalence of low eGFR but maintains similar predictive accuracy for mortality compared to the 2009 version. Findings support the use of the 2009 equation for population health monitoring in Mexico without compromising prognostic utility.

Keywords: *CKD-EPI, Chronic kidney disease, eGFR, Mexico, mortality.*

INTRODUCTION

Chronic kidney disease (CKD) has become a significant health problem worldwide, especially in low- and middle-income countries, were inequities in access to preventive services, renal replacement therapy (RRT), and the increasing prevalence of diabetes, hypertension, and high body mass index have contributed to growing prevalence and mortality estimations[1]. CKD diagnosis, stratification, and risk prediction typically involves estimation of the glomerular filtration rate (eGFR) and measuring albuminuria, with the former often estimated using a previously validated equation[2]. Previous clinical guidelines recommended using the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation which included coefficients to account for variability related to age, sex, and race[3,4]. However, the use of race in clinical algorithms has been recently questioned, especially in the United States, arguing that race is a social and not a biological construct[5]. Consequently, a new CKD-EPI equation without the race coefficient was developed in 2021[6], and the most recent clinical guidelines recommend avoiding the use of race for eGFR[2]. However, compared to directly measured GFR, the 2021 creatinine CKD-EPI equation introduces large and differential bias in both black and non-black individuals[6], which can significantly alter the population threshold for CKD diagnosis and, consequently, CKD prevalence in more homogeneous populations like Mexico. To date, no direct estimations of CKD prevalence have been conducted in Mexico, with prior studies focusing on forecasting estimates based on statistical models[1]. Furthermore, the utility of CKD-EPI equations for prediction of relevant outcomes, including all-cause and cause-specific mortality in Mexican populations has not been previously validated.

In this study, we aimed: (1) to estimate the prevalence of eGFR categories from 2016 to 2023 in Mexico, using the 2009 and 2021 CKD-EPI creatinine equations in adults recruited from the nationally representative National Health and Nutrition Survey (ENSANUT), (2) to estimate the prevalence and total number of individuals with low eGFR using either 2009

or 2021 CKD-EPI creatinine equations, (3) and to assess the performance of eGFR with both equations for prediction of all-cause and cardiovascular mortality in prospective cohort of adults living in Mexico City.

METHODS

Study populations

Mexican National Health and Nutrition Survey

We used data from the cross-sectional Mexican National Health and Nutrition Survey (ENSANUT) cycles 2016, 2018, 2020, 2021, 2022, and 2023. ENSANUT is a probabilistic survey representative at a regional and national level which uses a multi-stage probabilistic cluster stratified sampling design[7]. Sample weights are corrected using the response rate observed from the immediate previous cycle and calibrated to account for representation of specific subgroups. Participants completed a questionnaire including demographic, socioeconomic, and health-related information, along with a physical examination. Additionally, serum samples were collected from a random subsample per cycle to measure fasting glucose, serum creatinine, lipid profile, and glycated hemoglobin[7]. Further details on ENSANUT's methodology are reported elsewhere[7–10]. For prevalence estimations, we included individuals aged ≥20 years with complete and available serum creatinine measurements for eGFR.

Mexico City Prospective Study

The Mexico City Prospective Study (MCPS) is a population-based, prospective cohort study with a baseline survey conducted from 1998 to 2004 on two urban districts of Mexico City (Coyoacán and Iztapalapa)[11]. In total, 159,755 individuals aged 35 years were recruited and underwent a comprehensive questionnaire collecting sociodemographic and health-related information. Clinical measurements (weight, height, and blood pressure) were also obtained, and a non-fasting 10-mL blood sample was collected for subsequent analysis. Blood samples were stored in a central laboratory, separated into plasma and

buffy coat, and then frozen to $-80^{\circ}C$. From 2018 to 2024, every available plasma sample from the baseline examination was analyzed using nuclear magnetic resonance (NMR) spectroscopy at Nightingale Health Ltd (Kuopio, Finland) and the Clinical Trial Service Unit's Wolfson Laboratory, quantifying over 249 plasma biomarkers including creatinine, as described previously[12]. Creatinine values obtained by NMR were converted to mg/dL using the formula (creatinine [mmol] x 1000) / 88.42. For the assessment of both equations' performance, we included every participant aged ≥35 years with complete mortality, covariate, and serum creatinine data. Mortality follow-up of participants was done through electronic probabilistic linkage to death registries, with deaths tracked up to September 30th, 2022, and registered according to the International Classification of Diseases 10th Revision (ICD-10)[13]. Mortality analyses were estimated for all-cause and cardiovascular mortality (myocardial infarction for codes 120-I25, stroke for codes I60-I69) in accordance with the underlying causes of death determined by study clinicians. The study protocol was approved by the corresponding ethics committees at the Mexican Ministry of Health, the Mexican National Council for Science and Technology, and the University of Oxford, and every study participant provided written informed consent.

Variable definitions

Estimated glomerular filtration rate and chronic kidney disease

eGFR in both ENSANUT and MCPS was obtained using the CKD-EPI 2009 and 2021 creatinine-based equations[6]. eGFR was classified into six categories as recommended by KDIGO clinical practice guidelines, specifically: G1 normal or high (≥90 mL/min per 1.73 m^2), G2 mildly decreased (60–89 mL/min/1.73 m^2), G3a mildly to moderately decreased (45–59 mL/min/1.73 m^2), G3b moderately to severely decreased (30–44 mL/min/1.73 m^2), G4 severely decreased (15-29 mL/min/1.73 m^2), and G5 kidney failure (<15 mL/min/1.73 m^2)[3]. In both datasets, low eGFR was used as a proxy for chronic kidney disease (CKD) and was defined as eGFR <60 mL/min/1.73 m^2. Given that neither study performed

measurements of albuminuria or creatinine urinary excretion, we were unable to include the urine albumin-to-creatinine ratio (ARC) in our analyses. In supplementary analyses we also explored the prevalence of CKD defined as the combination of previous self-reported medical diagnosis of CKD or low eGFR.

Comorbidities

In ENSANUT, diabetes mellitus was defined as any participant with self-reported medical diagnosis of diabetes, or fasting plasma glucose of ≥126 mg/dL, or HbA1c ≥6.5%. Due to the lack of fasting plasma glucose measurement in MCPS, we defined diabetes as any participant with self-reported medical diagnosis of diabetes (including those reporting use of glucose-lowering medication), or HbA1c ≥6.5%[14]. In both datasets, hypertension was defined as any participant with either systolic (SBP) or diastolic blood pressure (DBP) ≥130/80 mmHg, and obesity as those with a calculated body mass index (BMI) ≥30 kg/m2.

Statistical analyses

Weighted prevalence estimations in ENSANUT

We obtained weighted prevalence of eGFR categories and low eGFR using the 2021 CKD-EPI creatinine-based equation, taking into consideration the complex survey design and using sample weights from ENSANUT. Additionally, we estimated low eGFR prevalence stratified by age categories (<60 or ≥60 years old), sex, diabetes, hypertension, and obesity status. Next, we compared these estimations against the 2009 CKD-EPI creatinine-based equation, exploring the proportion, and total number of individuals that would be reclassified from having CKD. For all estimates, we included only ENSANUT participants with available creatinine measurements and recalculated all sample weights accordingly.

Mortality predictive performance and clinical benefit of eGFR equations in MCPS

To evaluate the predictive performance of eGFR estimated with either 2009 or 2021 CKD-EPI creatinine-based equations, we fitted a baseline Cox proportional hazards model

stratified by baseline age category (35-44 years, 45-54 years, 55-64 years, 65-74 years, ≥75 years) and adjusted for sex, place of residence (Coyoacán or Iztapalapa), educational level (elementary, high school, university, other), smoking, diabetes, history of cardiovascular disease (previous self-reported diagnosis of angina, or myocardial infarction, or stroke), SBP (as a continuous variable), and total cholesterol (as a continuous variable). This model is very similar to the one previously validated by the Chronic Kidney Disease Prognosis Consortium for all-cause and cardiovascular mortality risk in multiple populations[15]. To this baseline model, we added either eGFR estimated with either 2009 or 2021 CKD-EPI equations, and then obtained metrics of discrimination and overall performance[16,17]. We applied administrative censoring at 10 years of follow-up to determine the added mortality predictive value at 5 years and 10 years of follow-up. The non-linear relationship between eGFR and mortality risk was investigated with penalized smoothing splines[18] and eGFR (estimated with CKD-EPI 2009 or 2021 equations) was modeled using restricted cubic splines with 5 knots determined according to the underlying eGFR distribution[19]. Fixed time point and time range assessment of discrimination was done using Harrell's c-statistic, and overall performance was determined evaluating changes in the model's Chi-square statistic, the Brier score, and the scaled Brier score at 5 and 10 years of follow-up. Even though relative hazards estimations might be inadequate to determine the added predictive value of a marker[16], we report the hazard ratio for either eGFR 2009 or eGFR 2021 on the extended models as a continuous variable. All statistical analyses were conducted using R software version 4.4.2.

RESULTS

eGFR categories and CKD prevalence in Mexican population

We analyzed data from 25,236 adults ≥20 years from six ENSANUT surveys during the 2016-2023 period with complete creatinine data (**Supplementary Table 1**). Using the 2021 CKD-EPI creatinine-based equation, the prevalence of eGFR categories was relatively

stable. The proportion of individuals on the G1 category was high, with a prevalence of 87.1% (95%CI 84.3–89.9%) in 2023, obtaining similar estimations for every year and a slightly decreasing trend over time (**Figure 1A**). G2 prevalence was much lower, with a prevalence of 10% (95%CI 7.8–12.2%) in 2023, once again presenting small variations during the study period (**Figure 1B**). G3a and G3b categories had a prevalence of 1.71% (95%CI 0.73–2.69%) and 0.83% (95%CI 0.19–1.47%), respectively (**Figure 1C**), and G4 and G5 prevalence estimations from 2016 to 2023 were below 0.5% and 0.25%, respectively. (**Table 1**). Overall categories G3a-G5 were stable over time but presented an increase during the 2020-2023 cycles.

In 2023, the prevalence of CKD in Mexico estimated solely from low eGFR was 2.8% (95%CI 1.47–4.13%), remaining relatively stable from 2016 to 2022, and showing a slight increase in 2023 (**Figure 1D, Table 1**). Prevalence was similar between men and women, but significantly higher among adults ≥60 years (**Figure 1E, F**). As expected, low eGFR prevalence was higher in individuals with diabetes and increased over time, reaching 8.5% (95%CI 4.18–12.82%) in 2023. This was also observed for individuals with hypertension, with a prevalence of 5.4% (95%CI 2.53 –8.27) in 2023 (**Figure 1G, H**). Similar trends of low eGFR prevalence were found among individuals with and without obesity, with estimations around 2% from 2016 to 2023 (**Figure 1I**). The estimated total number of individuals with CKD defined by low eGFR in Mexico ranged from 1,264,500 (95%CI 821,846–1,707,154) in 2016 to 2,135,956 (95%CI 1,111,388–3,160,524) in 2023 (**Supplementary Table 2**).

Comparison of low eGFR prevalence using different CKD-EPI equations in ENSANUT

eGFR was consistently higher using the 2021 CKD-EPI equation, with a median of 111.27 (IQR 99.1–121.1) compared to a median of 107.9 (IQR 95.1–119.4) using the 2009 CKD-EPI equation (**Figure 2A, Supplementary Table 3**). Consequently, low eGFR prevalence was higher using the 2009, compared to the 2021 CKD-EPI equation. Using the former,

low eGFR prevalence in 2023 was 3.4% (95%CI 1.79–5.01) compared to a slightly lower estimation of 2.8% (95%CI 1.47–4.13%) with the latter (**Figure 2B, Supplementary Table 2**). This trend persisted regardless of survey cycle, sex, age, diabetes, or hypertension status (**Figure 2C–F**). Notably, the difference between equations was much lower among individuals with higher eGFR (i.e. participants <60 years, or without diabetes, or without hypertension). Using the CKD-EPI 2021 equation resulted in upward reclassification (i.e. an individual classified as G3a with the 2009 CKD-EPI equation reclassified as G2 using the 2021 CKD-EPI equation), and reclassified individuals across eGFR categories were predominately men, older, had a higher proportion of diabetes, and hypertension compared to those not reclassified (**Supplementary Table 4**). The higher eGFR using the 2021 compared with the 2009 CKD-EPI equation, translated into an absolute reduction of the total number of individuals that would be diagnosed with CKD using only eGFR. Specifically, adoption of 2021 CKD-EPI equation would have resulted in 247,962 less individuals with CKD in 2016 and 496,362 less in 2023 (**Supplementary Table 5**). Prevalence estimations including CKD defined as the combination of previous self-reported medical diagnosis of CKD or low eGFR estimated by either creatinine equation can be found in **Supplementary Table 4,** and **Supplementary Figure 1.**

Predictive performance of eGFR estimated using different CKD-EPI equations

Among 159,517 participants recruited from 1998 to 2004 in MCPS, 143,410 had complete covariate and mortality data, and were included in the analyses. At the 10-year administrative censoring, there were 6,093 all-cause deaths, 3,249 among women and 2,844 among men. Similar to our findings in ENSANUT, eGFR distribution was higher using the 2021 compared to the 2009 CKD-EPI equation (**Figure 3A**), and the prevalence of each eGFR category and CKD using low eGFR prevalence were lower when estimating eGFR with the 2021 CKD-EPI equation (**Supplementary Table 6, Supplementary Table 7**).

Relative risk estimations for all-cause mortality were similar between equations in both extended models, with slightly lower HRs when using the 2021 equation, particularly at higher eGFR values (**Figure 3B**). Evaluating the 5-year performance for all-cause mortality, we found a significant increase in the models' Chi-square statistic, from 1985.4 on the baseline model to 3687.7 by adding eGFR 2009 (LR test 1702.3, df = 4, p <0.001), and 3690 by adding eGFR 2021 (LR test 1704.4, df = 4, p <0.001). A smaller increase was observed at 10 years of follow-up, were the baseline model's chi-square statistic increased from 1744.4 to 1949.9 by adding eGFR 2009 (LR test 205.5, df = 4, p <0.001) and 1948.9 by adding eGFR 2021 (LR test 204.5, df = 4, p <0.001). Time range discrimination improved moderately from 0.665 (95% CI 0.658–0.673) on the baseline model to 0.672 (95%CI 0.664–0.680) by adding either eGFR 2009 or eGFR 2021 (**Table 2**). However, when assessing fixed point discrimination throughout the follow-up period, a higher discrimination for the extended models was observed during the first 5 years of follow-up compared to the baseline model, with a similar c-statistics for both eGFR 2009 and eGFR 2021 (**Figure 3C**). Fixed-point discrimination past 5 years and up to 10 years of follow-up was virtually identical for baseline and extended models (**Figure 3D**). At 5 years of follow-up, the baseline model's Brier score decreased from 0.036 (95%CI 0.035–0.037) to 0.035 (95%CI 0.034–0.036) when including either eGFR 2009 or eGFR 2021, and the scaled Brier score increased from 9.37 to 12.95% when including eGFR 2009, and to 12.98% when including eGFR 2021. Interestingly, at 10 years of follow-up, the Brier score was virtually identical for the baseline model and both extended models, and the scaled Brier score increased only slightly from 16.11% on the baseline model to 16.50% for both extended models (**Table 2**). Predictive performance of eGFR on cardiovascular mortality were relatively similar and the extended results can be found on **Supplementary Table 8**.

DISCUSSION

To our knowledge, this is the first study estimating the prevalence of eGFR categories and CKD from low eGFR using a nationally representative sample in Mexico. Our results using the 2021 CKD-EPI creatinine equation, show relatively stable prevalence estimates of eGFR categories from 2016 to 2023, with a CKD prevalence of 2.8% in 2023 based only on low eGFR, and similar estimates during the study period. When comparing eGFR between equations, estimates were consistently lower using the 2009 CKD-EPI equation and, consequently, there was a persistent pattern of upward reclassification adopting the newest 2021 CKD-EPI creatinine equation. Accordingly, CKD prevalence based only on low eGFR estimated with the 2009 CKD-EPI equation was slightly higher than that obtained using the 2021 CKD-EPI equation, with an estimation of 3.4% for 2023. The predictive performance of eGFR obtained with either equation was relatively similar when evaluating overall performance, time-range, and fixed-point discrimination for 10-year all-cause mortality, which suggest comparable effectiveness in risk estimation. Therefore, our results suggest no significant changes in CKD stage reclassification with either CKD-EPI equation. Conversely, we support the view that the choice of equation for eGFR should be oriented primarily with a public-health perspective and should be made based on individual countries' population structures.

Previous reports have estimated CKD prevalence in Mexico relying on heterogeneous data sources and statistical methods[21,22], or in specific geographical locations[23–26]. An analysis for the Global Burden of Disease estimated around 14.5 million prevalent cases of CKD in Mexico on 2017[1], which contrast significantly with our estimations using nationally representative survey data. Regardless of the equation used, and based solely on eGFR, ENSANUT data show around 2 million individuals with CKD in 2023 and around 2.5 million individuals when considering prior diagnosis of CKD. However, the absence of albuminuria categories might lead to a significant prevalence underestimation, and the lack of the three month chronicity period may lead to some overestimation[27]. Nevertheless, the results of

our study are based on direct creatinine measurements, which are more reliable than estimations inferred from statistical methods, and are not limited to specific geographical locations. Further studies are warranted to provide more accurate nationally representative estimates of CKD in Mexico, considering chronicity, albuminuria, GFR estimates based on cystatin C measures, or the number of RRT users.

Impaired fasting glucose, hypertension, and high body mass index represent the most important risk factors for CKD[1,28], all of which are highly prevalent in Mexico and usually associated with very poor metabolic control[29–31]. Accordingly, our estimations using ENSANUT data show higher prevalence of low eGFR among individuals with diabetes, and hypertension, which highlights the importance of comprehensive risk factor control to avoid the increasing mortality rates[22] and significant costs related to CKD in Mexico[32]. Interestingly, we did not find higher consistently higher prevalence estimates among individuals with obesity and, despite previous studies reporting greater prevalence of CKD among women[33], our findings did not reveal a distinct pattern between sexes.

Recent clinical guidelines in the United States have advocated for the implementation of eGFR creatinine-based equations without a race coefficient or increased adoption of cystatin C based equations[2]. This recommendations has, however, raised concerns given that the 2021 CKD-EPI creatinine equation introduces large and differential bias in both black and non-black individuals[6]. Additionally, in relatively homogeneous populations like Mexico, the implementation of the 2021 CKD-EPI equation does not seem to bring any added benefits, but rather the introduction of bias when estimating GFR. Similar to our estimations, previous studies in diverse populations have reported higher eGFR distribution, and lower CKD prevalence using the 2021 CKD-EPI equation, with upward reclassification especially among men, and older individuals[34–36]. Given these results, along with the possibility of inaccuracies when determining eGFR at an individual level and significant implications on public health decision making, several authors and societies

have recommended maintaining the use of the 2009 CKD-EPI equation until a better alternative is available or develop region-specific validated equations. Mexican clinical guidelines on CKD were last updated in 2019 and they recommend GFR estimation with either Cockroft-Gault equation, the Modification of Diet in Renal Disease (MDRD) equation, or the 2009 CKD-EPI creatinine equation[37]. It should be noted that the Cockroft-Gault equation is a creatinine clearance equation and the MDRD equation systematically underestimates GFR at GFR >60 mL/min/1.73 m^2 [38]. Furthermore, considering the limitations of the newest 2021 CKD-EPI equation, the results of this study suggest that the 2009 CKD-EPI creatinine equation remains a reasonable choice for populations like that of Mexico, which is relatively homogeneous and comprised mainly of individuals with Hispanic descent. Additionally, creatinine measurements are widely used across the country to evaluate kidney function in clinical practice, and due to cost constraints, widespread implementation of cystatin C testing in Mexico remains a distant prospect.

Our study has several strengths. To our knowledge, this is the first study estimating GFR and CKD prevalence directly from creatinine measurements in Mexico, rather than relying on statistical methods to infer prevalence estimates. Additionally, given the availability of data since 2016, we were able to obtain nationally representative estimates of eGFR and CKD from the last six surveys, which give the most recent trends of CKD prevalence. Furthermore, access to data from a prospective study with mortality follow-up, allowed us to evaluate the risk prediction performance of eGFR estimated with either CKD-EPI equation in a predominately Hispanic population, broadening similar results in mostly white and European countries. However, some limitations should be considered to adequately interpret our results. First, CKD prevalence was estimated considering only low eGFR, and we were unable to include albuminuria to classify individuals as recommended by clinical guidelines[2]. Second, given the cross-sectional nature of the study, our definition of CKD relied on a single creatinine measurement, which lacks the three-month chronicity

criterion, leading to a potential overestimation of CKD prevalence. Notably, our estimates did not account for the use of RRT. Finally, due to the lack of data, we were unable to evaluate eGFR and CKD prevalence using the creatinine and cystatin C equation, which has been reported as the most accurate[6].

In conclusion, eGFR and CKD prevalence based on low eGFR in Mexico have been relatively stable over time, with some recent increases in 2023. As reported in predominately white Europeans, the new 2021 CKD-EPI equation consistently estimates higher GFR levels, which translates to lower CKD prevalence estimates and upward reclassification predominately in men and older individuals. Additionally, risk prediction performance of eGFR estimated with either equation was very similar. Given the presence of differential bias in eGFR when using the 2021 CKD-EPI equation, and the relatively homogeneous Hispanic population in Mexico, our findings support continued consideration of the 2009 CKD-EPI equation as a valid and reliable option for estimating eGFR in Mexico.

ACKNOWLEDGMENTS

This project was registered and approved by the Research Committee at Instituto Nacional de Geriatría, project number DI-PI-009-2024. JPE and CAFM are enrolled at the PECEM Program of the Faculty of Medicine at UNAM and are supported by CONACyT. JAS was supported by Grant Number K23DK135798 from the NIH/NIDDK and by the Massachusetts General Hospital Executive Committee and Center for Diversity and Inclusion Physician-Scientist Development Award. This research was conducted using Mexico City Prospective Study (MCPS) data obtained through an open-access data request (application number 2022-012). MCPS is a long-standing scientific collaboration between researchers at the National Autonomous University of Mexico and the University of Oxford, and has received funding from the Mexican Health Ministry, the National Council

of Science and Technology for Mexico, Wellcome, Cancer Research UK, the British Heart Foundation, Kidney Research UK and the UK Medical Research Council. The authors thank the participants for their willingness to take part in this prospective study 20 years ago.

AUTHOR CONTRIBUTIONS

Research idea and study design: DRG, CAFM, PSC, OYBC; data acquisition: CAFM, DRG, PSC, JAD, PKM, JBC, RTC, OYBC; analysis/interpretation: DRG, CAFM, OYBC; statistical analysis: DRG, CAFM, OYBC; manuscript drafting: DRG, CAFM, PSC, BGCF, JPE, JPDS, KBCH, LACQ, JCB, PKM, RTC, JAD, NEAV, JAS, OYBC; supervision or mentorship: OYBC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

DATA AVAILABILITY: All code and materials regarding ENSANUT are available for reproducibility of results http://github.com/oyaxbell/ckdepi_mcps_ensanut/. Data from the Mexico City Prospective Study are available to bona fide researchers. For more details, the study's Data and Sample Sharing policy may be downloaded (in English or Spanish) from https://www.ctsu.ox.ac.uk/research/mcps. Available study data can be examined in detail through the study's Data Showcase, available at https://datashare.ndph.ox.ac.uk/mexico/.

CONFLICT OF INTEREST/FINANCIAL DISCLOSURE: Nothing to disclose.

FUNDING: This research was supported by Instituto Nacional de Geriatría in Mexico.

ETHICAL DISCLOSURES: This project was registered and approved by the Research Committee at Instituto Nacional de Geriatría, project number DI-PI-009-2024. MCPS was approved by Ethics Committees at the Mexican Ministry of Health, the Mexican National

Council for Science and Technology, and the University of Oxford, UK. All MCPS participants provided written informed consent.

REFERENCES

1. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-6736(20)30045-3

2. Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*. 2024;105(4):S117-S314. doi:10.1016/j.kint.2023.10.018

3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Inter*. 2013;Suppl.(3):1-150.

4. Levey AS, Stevens LA, Schmid CH, et al. A New Equation to Estimate Glomerular Filtration Rate. *Ann Intern Med*. 2009;150(9):604. doi:10.7326/0003-4819-150-9-200905050-00006

5. Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. *J Am Soc Nephrol*. 2021;32(12):2994-3015. doi:10.1681/ASN.2021070988

6. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *N Engl J Med*. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953

7. Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, et al. Metodología de la Encuesta Nacional de Salud y Nutrición 2022 y Planeación y diseño de la Ensanut Continua 2020-2024. *Salud Pública México*. 2022;64(5, sept-oct):522-529. doi:10.21149/14186

8. Romero-Martínez M, Shamah-Levy T, Cuevas-Nasu L, et al. Diseño metodológico de la Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. *Salud Pública México*. 2017;59(3, may-jun):299. doi:10.21149/8593

9. Romero-Martínez M, Shamah-Levy T, Vielma-Orozco E, et al. Encuesta Nacional de Salud y Nutrición 2018-19: metodología y perspectivas. *Salud Pública México*. 2019;61(6, nov-dic):917-923. doi:10.21149/11095

10. Romero Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, et al. Metodología de la Encuesta Nacional de Salud y Nutrición 2021. *Salud Pública México*. 2021;63(6, Nov-Dic):813-818. doi:10.21149/13348

11. Tapia-Conyer R, Kuri-Morales P, Alegre-Díaz J, et al. Cohort Profile: The Mexico City Prospective Study. *Int J Epidemiol*. 2006;35(2):243-249. doi:10.1093/ije/dyl042

12. Aguilar-Ramirez D, Herrington WG, Alegre-Díaz J, et al. Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults. *Commun Med*. 2022;2(1):143. doi:10.1038/s43856-022-00208-2

13. Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and Cause-Specific Mortality in Mexico City. *N Engl J Med*. 2016;375(20):1961-1971. doi:10.1056/NEJMoa1605368

14. American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. *Diabetes Care*. 2024;47(Supplement_1):S20-S42. doi:10.2337/dc24-S002

15. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *The Lancet*. 2010;375(9731):2073-2081. doi:10.1016/S0140-6736(10)60674-5

16.   Steyerberg EW, Pencina MJ, Lingsma HF, Kattan MW, Vickers AJ, Van Calster B. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. *Eur J Clin Invest*. 2012;42(2):216-228. doi:10.1111/j.1365-2362.2011.02562.x

17.   McLernon DJ, Giardiello D, Van Calster B, et al. Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models. *Ann Intern Med*. 2023;176(1):105-114. doi:10.7326/M22-0844

18.   Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. Springer; 2000.

19.   Harrell FE. *Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis*. Second edition. Springer; 2015.

20.   Vickers AJ, Elkin EB. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models. *Med Decis Making*. 2006;26(6):565-574. doi:10.1177/0272989X06295361

21.   Argaiz ER, Morales-Juárez L, Razo C, et al. La carga de enfermedad renal crónica en México. Análisis de datos basado en el estudio *Global Burden of Disease* 2021. *Gac Médica México*. 2023;159(6):12575. doi:10.24875/GMM.23000393

22.   Agudelo-Botero M, Valdez-Ortiz R, Giraldo-Rodríguez L, et al. Overview of the burden of chronic kidney disease in Mexico: secondary data analysis based on the Global Burden of Disease Study 2017. *BMJ Open*. 2020;10(3):e035285. doi:10.1136/bmjopen-2019-035285

23.   Gutierrez-Peña M, Zuñiga-Macias L, Marin-Garcia R, et al. High prevalence of end-stage renal disease of unknown origin in Aguascalientes Mexico: role of the registry of chronic kidney disease and renal biopsy in its approach and future directions. *Clin Kidney J*. 2021;14(4):1197-1206. doi:10.1093/ckj/sfaa229

24.   Aguilar-Ramirez D, Raña-Custodio A, Villa A, et al. Decreased kidney function and agricultural work: a cross-sectional study in middle-aged adults from Tierra Blanca, Mexico. *Nephrol Dial Transplant*. 2021;36(6):1030-1038. doi:10.1093/ndt/gfaa041

25.   Amato D, Alvarez-Aguilar C, Castaneda-Limones R, et al. Prevalence of chronic kidney disease in an urban Mexican population. *Kidney Int*. 2005;68:S11-S17. doi:10.1111/j.1523-1755.2005.09702.x

26.   Obrador GT, García-García G, Villa AR, et al. Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) México and comparison with KEEP US. *Kidney Int*. 2010;77:S2-S8. doi:10.1038/ki.2009.540

27.   Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl*. 2022;12(1):7-11. doi:10.1016/j.kisu.2021.11.003

28.   Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. *Nat Rev Dis Primer*. 2017;3(1):17088. doi:10.1038/nrdp.2017.88

29.   Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. *Salud Pública México*. 2023;65:s163-s168. doi:10.21149/14832

30.   Campos-Nonato I, Oviedo-Solís C, Vargas-Meza J, et al. Prevalencia, tratamiento y control de la hipertensión arterial en adultos mexicanos: resultados de la Ensanut 2022. *Salud Pública México*. 2023;65:s169-s180. doi:10.21149/14779

31.   Campos-Nonato I, Galván-Valencia Ó, Hernández-Barrera L, Oviedo-Solís C, Barquera S. Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022. *Salud Pública México*. 2023;65:s238-s247. doi:10.21149/14809

32.   Figueroa-Lara A, Gonzalez-Block MA, Alarcon-Irigoyen J. Medical Expenditure for Chronic Diseases in Mexico: The Case of Selected Diagnoses Treated by the Largest Care Providers. Griffiths UK, ed. *PLOS ONE*. 2016;11(1):e0145177.

doi:10.1371/journal.pone.0145177

33.   Mills KT, Xu Y, Zhang W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. *Kidney Int*. 2015;88(5):950-957. doi:10.1038/ki.2015.230

34.   Fu EL, Coresh J, Grams ME, et al. Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population. *Nephrol Dial Transplant*. 2023;38(1):119-128. doi:10.1093/ndt/gfac197

35.   Vestergaard SV, Heide-Jørgensen U, Birn H, Christiansen CF. Effect of the Refitted Race-Free eGFR Formula on the CKD Prevalence and Mortality in the Danish Population. *Clin J Am Soc Nephrol*. 2022;17(3):426-428. doi:10.2215/CJN.14491121

36.   Gregg LP, Richardson PA, Akeroyd J, Matheny ME, Virani SS, Navaneethan SD. Effects of the 2021 CKD-EPI Creatinine eGFR Equation among a National US Veteran Cohort. *Clin J Am Soc Nephrol*. 2022;17(2):283-285. doi:10.2215/CJN.10000721

37.   CENETEC. Prevención, Diagnóstico y Tratamiento de la Enfermedad Renal Crónica. Guía de Evidencias y Recomendaciones: Guía de Práctica Clínica. Published online 2019.

38.   Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. *J Am Soc Nephrol JASN*. 2007;18(10):2749-2757. doi:10.1681/ASN.2007020199

TABLES

eGFR categories						
Category	**2016**	**2018**	**2020**	**2021**	**2022**	**2023**
G1	88.92% (87.26-90.58)	87.39% (86.36-88.43)	89.88% (88.47-91.30)	85.82% (83.57-88.07)	89.02% (86.96-91.07)	87.18% (84.38-89.97)
G2	9.28% (7.74-10.82)	10.63% (9.67-11.60)	8.23% (6.96-9.50)	12.06% (9.98-14.14)	9.13% (7.21-11.06)	10.03% (7.82-12.24)
G3a	0.93% (0.53-1.34)	1.06% (0.81-1.31)	0.97% (0.54-1.40)	1.09% (0.49-1.70)	0.73% (0.36-1.10)	1.71% (0.73-2.69)
G3b	0.37% (0.15-0.60)	0.52% (0.29-0.74)	0.48% (0.13-0.82)	0.32% (0.03-0.61)	0.40% (0.12-0.69)	0.83% (0.19-1.47)
G4	0.14% (0.01-0.27)	0.26% (0.14-0.38)	0.22% (0.03-0.41)	0.57% (0.00-1.38)	0.53% (0.00-1.24)	0.00% (0.00-0.01)
G5	0.35% (0.00-0.71)	0.14% (0.06-0.22)	0.22% (0.05-0.39)	0.14% (0.00-0.37)	0.18% (0.01-0.36)	0.25% (0.00-0.53)
Chronic Kidney Disease						
eGFR <60 mL/min 1.73 m^2	1.8 (1.16–2.44)	2.0 (1.62–2.38)	1.9 (1.29–2.51)	2.1 (1.03–3.17)	1.9 (1.03–2.77)	2.8 (1.47–4.13)

Table 1. Nationally representative eGFR categories prevalence from 2016 to 2023 using ENSANUT data. eGFR was estimated using the CKD-EPI 2021 creatinine-based equation. G1 normal or high (≥90 mL/min per 1.73 m^2), G2 mildly decreased (60–89 mL/min/1.73 m^2), G3a mildly to moderately decreased (45–59 mL/min/1.73 m^2), G3b moderately to severely decreased (30–44 mL/min/1.73 m^2), G4 severely decreased (15-29 mL/min/1.73 m^2), and G5 kidney failure (<15 mL/min/1.73 m^2). eGFR: Estimated glomerular filtration rate, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration.

	Discrimination assessment	Overall performance			
	Harrell C-statistic	Brier score (5 year)	Scaled Brier score (5 year)	Brier score (10 year)	Scaled Brier score (10 year)
Baseline model	0.665 (95% CI 0.658–0.673)	0.036 (95%CI 0.035–0.037)	9.37%	0.038 (95%CI 0.037–0.039)	16.11%
+ eGFR 2009	0.672 (95%CI 0.665–0.680)	0.035 (95%CI 0.034–0.036)	12.95%	0.037 (95%CI 0.037–0.038)	16.50%
+ eGFR 2021	0.672 (95%CI 0.664–0.680)	0.035 (95%CI 0.034–0.036)	12.98%	0.037 (95%CI 0.037–0.038)	16.50%

Table 2. Discrimination assessment and overall performance assessment of all-cause mortality for the baseline model and both extended models in participants of the Mexico City Prospective Study. The baseline model was stratified by age category and adjusted for sex, place of residence (Coyoacán or Iztapalapa), educational level (elementary, high school, university, other), smoking, diabetes, history of cardiovascular disease, systolic blood pressure, and total cholesterol. eGFR: Estimated glomerular filtration rate.

FIGURES

Figure 1. Prevalence of eGFR categories and CKD based on low eGFR in Mexico using the 2021 CKD-EPI creatinine equation in ENSANUT 2016-2023 data. (A) G1, (B) G2, (C) G3a, G3b, G4, and G5, (D) Overall CKD prevalence and CKD prevalence stratified by (E) sex, (F) age category, (G) diabetes, (H) hypertension, and (I) obesity status. G1 normal or high (≥90 mL/min per 1.73 m^2), G2 mildly decreased (60–89 mL/min/1.73 m^2), G3a mildly

to moderately decreased (45–59 mL/min/1.73 m^2), G3b moderately to severely decreased (30–44 mL/min/1.73 m^2), G4 severely decreased (15-29 mL/min/1.73 m^2), and G5 kidney failure (<15 mL/min/1.73 m^2). eGFR: Estimated glomerular filtration rate, CKD: Chronic Kidney Disease, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration.

Figure 2. eGFR distribution and comparison of CKD prevalence using either 2021 or 2009 CKD-EPI creatinine equations in ENSANUT 2016-2023 data. (A) eGFR distribution, (B) Comparison of overall CKD prevalence using both equations, (C) Comparison of CKD prevalence in men, (D) age category, (E) diabetes status, and (F) hypertension status. eGFR: Estimated glomerular filtration rate, CKD: Chronic Kidney Disease, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration.

Figure 3. eGFR distribution and all-cause mortality risk prediction performance of eGFR estimated with either 2021 or 2009 CKD-EPI creatinine equation in the Mexico City Prospective Study. (A) Comparison of eGFR distribution in MCPS, (B) Comparison of HRs estimations across continuous eGFR levels, (C) 5-year discrimination assessment of eGFR estimated with either 2009 or 2021 CKD-EPI creatinine equation, (D) 10-year discrimination assessment of eGFR estimated with either 2009 or 2021 CKD-EPI creatinine equation. In both C and D, the gray line represents the baseline model without the eGFR covariate. All models were stratified by age category and adjusted for sex, place of residence, educational level, smoking, diabetes, history of cardiovascular disease, systolic blood pressure, and total cholesterol. To this baseline model, GFR estimated with either the 2021 or 2009 CKD-EPI creatinine equation was added. eGFR: Estimated

glomerular filtration rate, CKD: Chronic Kidney Disease, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration.